HeartBeam, Inc. $BEAT

By Microcap Ledger desk · CIK 0001779372

Facts as of Oct 17, 2026, 6:36 PM EDT. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Rankings #6 for October volume increase (to date)#12 for October volume spike (to date)#15 for October spike and fade (to date)

Snapshot

Exchange: Nasdaq Capital Market
Sector: Surgical & Medical Instruments & Apparatus
Headquarters: Santa Clara, CA
Fiscal year end: December 31
Shares outstanding: 56,349,171 [10-Q 2026-08-13]
as of 2026-08-11

Sources: [10-K 2026-03-12]

What the company doesAI summary of filing

HeartBeam is a medical technology company that develops ambulatory cardiac monitoring solutions. Its initial product, the HeartBeam System, is an FDA-cleared, cable-free device that captures heart electrical signals in three dimensions and synthesizes them into a 12-lead ECG for arrhythmia assessment. The company generated no revenue in 2025 and is in the early commercialization stage, planning a limited market launch in early 2026 targeting concierge and preventive cardiology practices. HeartBeam makes money through sale or licensing of its devices and services, including physician portal access and on-demand cardiologist reviews, and plans to seek insurance reimbursement for broader adoption. [10-K 2026-03-12]

Segments: HeartBeam System (cable-free 12-lead ECG device), Extended wear patch monitor (in development), Smartwatch-based 12-lead ECG monitor (in development), AI-based cardiac disease detection algorithms

Price and volume

End-of-day figures only, previous close Oct 16, 2026. Not a live quote.

Previous close, Oct 16, 2026: $0.436+1.0% on the day
52-week high: $4.00Dec 17, 2025
52-week low: $0.355Sep 25, 2026
Avg dollar volume, 20 days: $14.26M
Last session volume: 0.02× vs prior 20-session average
Heavy-volume sessions: 2 of last 20 at 2× usual volume or more

High and low are intraday extremes from daily bars; dollar volume is each session's close times its share volume, averaged. Prices are adjusted for splits, so older prices may differ from what was quoted at the time. Data: [source]

Does $BEAT spike often?

In the last 250 sessions, $BEAT closed up 20% or more on 5 days.

Day	Close change	Volume	5 sessions later
Nov 28, 2025	+27.5%	100M	−5.2%
Dec 10, 2025	+92.4%	270M	+98.1%
Dec 11, 2025	+36.8%	160M	+27.8%
Dec 16, 2025	+30.8%	42.8M	−20.3%
Oct 5, 2026	+50.5%	404M	−35.0%

Regular-session closes. Highlighted bars are days up 20%+ close to close. "5 sessions later" is the close five trading days after, versus that day's close. History, not a forecast. Data: [source]

Why it moved

Our desk write-ups of past sharp moves in $BEAT, each sourced to filings and releases.

$BEAT Why did HeartBeam (BEAT) stock go up? FDA designation, not clearance ▲ +50.5% Oct 5, 2026 · Before the open, HeartBeam said the FDA granted Breakthrough Device designation to its system for assessing potential heart attacks at home. That is not marketing clearance for that use.

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
6 months to Jun 2026	—	−$9.74M	−$6.95M	$8.72M	[10-Q 2026-08-13]
FY ended Dec 2025	—	−$21.02M	−$13.99M	$4.38M	[10-K 2026-03-12]
FY ended Dec 2024	—	−$19.45M	−$14.47M	$2.38M	[10-K 2026-03-12]

Quarterly cash burn: −$3.48M
Cash runway Estimate: ~7.5 months

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-11-05	26,665,470	[10-Q 2024-11-07]
2025-03-11	33,725,467	[10-K 2025-03-13]
2025-05-09	33,806,786	[10-Q 2025-05-13]
2025-08-11	34,311,589	[10-Q 2025-08-13]
2025-11-11	34,443,563	[10-Q 2025-11-13]
2026-03-11	41,087,871	[10-K 2026-03-12]
2026-05-11	55,506,835	[10-Q 2026-05-13]
2026-08-11	56,349,171	[10-Q 2026-08-13]

Shelf registration: S-3 filed 2026-02-09; declared effective 2026-03-17 [S-3 2026-02-09]

Listing status

Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-07-02. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2026-07-02	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2026-07-02]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-07-24	Persen Kenneth Harry	grant	105,740	—	[4 2026-07-24]
2026-07-24	Cruickshank Tim	grant	167,760	—	[4 2026-07-24]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-08-14	8-K	Material agreement entered
2026-08-14	424B5	Prospectus or prospectus supplement
2026-08-13	13D/A	Beneficial ownership report (5%+ holder)
2026-08-13	10-Q	Quarterly report
2026-08-06	8-K	Director or officer change
2026-08-03	8-K	Shareholder vote results
2026-07-02	8-K	Listing notice or transfer
2026-06-24	8-K	Director or officer change; Other events
2026-06-22	8-K	Director or officer change
2026-06-18	DEF 14A	Proxy statement
2026-06-05	PRE 14A	Proxy statement
2026-05-13	10-Q	Quarterly report

Facts as of Oct 17, 2026, 6:36 PM EDT. Small caps move fast; check the latest filings.